Shattuck Labs, Inc. (NASDAQ:STTK) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shattuck Labs, Inc. (NASDAQ:STTK) has earned an average recommendation of “Moderate Buy” from the five ratings firms that are currently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation, two have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $3.00.

A number of analysts have issued reports on the company. Wedbush assumed coverage on Shattuck Labs in a research report on Monday, September 8th. They issued an “outperform” rating and a $4.00 target price on the stock. Leerink Partners cut their target price on Shattuck Labs from $4.00 to $2.00 and set an “outperform” rating on the stock in a research report on Thursday, August 14th. Needham & Company LLC reissued a “hold” rating on shares of Shattuck Labs in a research report on Thursday, August 14th. Finally, Wall Street Zen raised Shattuck Labs from a “sell” rating to a “hold” rating in a research report on Saturday, September 13th.

Shattuck Labs Stock Performance

STTK stock opened at $2.37 on Friday. The firm has a market cap of $113.52 million, a PE ratio of -1.96 and a beta of 1.89. The firm’s 50 day moving average price is $1.41 and its 200-day moving average price is $1.11. Shattuck Labs has a one year low of $0.69 and a one year high of $2.49.

Shattuck Labs (NASDAQ:STTK) last announced its earnings results on Thursday, August 14th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.01. Equities research analysts predict that Shattuck Labs will post -1.48 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Orbimed Advisors Llc acquired 6,306,127 shares of the business’s stock in a transaction dated Monday, August 25th. The shares were acquired at an average price of $0.87 per share, with a total value of $5,486,330.49. Following the completion of the transaction, the director owned 5,255,106 shares of the company’s stock, valued at $4,571,942.22. The trade was a -600.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Mona Ashiya acquired 6,306,127 shares of the business’s stock in a transaction dated Monday, August 25th. The shares were bought at an average cost of $0.87 per share, for a total transaction of $5,486,330.49. Following the transaction, the director directly owned 5,255,106 shares of the company’s stock, valued at approximately $4,571,942.22. This trade represents a -600.00% increase in their position. The disclosure for this purchase can be found here. 12.00% of the stock is currently owned by corporate insiders.

Institutional Trading of Shattuck Labs

A number of large investors have recently modified their holdings of the stock. Bridgeway Capital Management LLC increased its position in shares of Shattuck Labs by 147.5% during the second quarter. Bridgeway Capital Management LLC now owns 92,300 shares of the company’s stock worth $73,000 after acquiring an additional 55,000 shares during the period. 683 Capital Management LLC increased its position in shares of Shattuck Labs by 4.3% during the second quarter. 683 Capital Management LLC now owns 1,095,000 shares of the company’s stock worth $867,000 after acquiring an additional 45,000 shares during the period. Jane Street Group LLC increased its position in shares of Shattuck Labs by 2,510.8% during the second quarter. Jane Street Group LLC now owns 289,671 shares of the company’s stock worth $229,000 after acquiring an additional 278,576 shares during the period. Qube Research & Technologies Ltd purchased a new stake in shares of Shattuck Labs during the second quarter worth $44,000. Finally, Pinnacle Associates Ltd. increased its holdings in Shattuck Labs by 4.9% in the second quarter. Pinnacle Associates Ltd. now owns 1,363,723 shares of the company’s stock valued at $1,080,000 after buying an additional 64,000 shares during the last quarter. Hedge funds and other institutional investors own 58.74% of the company’s stock.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.